References
- 1. http://www.allelefrequencies.net/diseases/
- 2. Mandelboim O, Reyburn H, Vales-Gomez M, et al. Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J Exp Med, 1996, 184, 913-922.
- 3. Collona M, Samaridis S. Cloning of immunoglobulin-super-family members associated with HLA-C and HLA-B recognition by human natural killer cells. Science, 1995, 268: 405-408.
- 4. Foley B, De Santis D, Van Beelen E, et al. The reactivity of Bw4+ HLA-B and HLA-A alleles with KIR3DL1:implications for patient and donor suitability for haploidentical stem cell rans-plantations. Blood, 2008, 112, 435-443.
- 5. Gumperz J, Litwin V, Philips J et al. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med, 1995; 181, 1133-1144.
- 6. Hansasuta P, Dong T, Thananchi H, et al. Recognition of HLAA3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur J Immunol, 2004, 34, 1673-1679.
- 7. Biassoni R, Pessino A, Malaspina A, et al. Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur J Immunol, 1997, 27, 3095-3099.
- 8. Stewart C, Laugier-Anfossi F, Vely F, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA, 2005, 102, 13224-13229.
- 9. Single R, Martin MP, Gao X, et al. Global diversity and evidence for coevolution of KIR and HLA. Nat Genet, 2007, 39, 1114-1119.
- 10. Alter G, Martin MP, Teigen N, et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med, 2007, 204, 3027-3036.
- 11. Khakoo SI, Carrington M. KIR and disease: a model system or system of models. Immunol Rev, 2006, 214, 186-201.
- 12. Karabon L, Jedynak A, Giebel S, et al. KIR/HLA gene combinations influence susceptibility to B-cell chronic lymphocytic leukemia and the clinical course of disease. Tissue Antigens, 2011, 78, 129-138.
- 13. Besson C, Roetync S, Williams F, et al. Association of killer cell immunoglobulin-like receptor genes with Hodgkin lymphoma in a familial study. PLoS ONE, 2007, 2(5), e406.
- 14. Shahsavar F, Tajik N, Entezami K, et al. KIR2DS3 is associated with protection against acute myeloid leukemia. Iran J Immunol, 2010, 7, 8-17.
- 15. Verheyden S, Demanet C. Susceptibility to myeloid and lymphoid leukemia is mediated by distinct inhibitory KIR-HLA ligand interactions. Leukemia, 2006, 20, 1437-1438.
- 16. Pamuk GE, Tozkir H, Uyanik MS, et al. Natural killer cell killer immunoglobulin-like gene receptor polymorphisms in non-Hodgkin lymphoma: possible association with clinical course. Leuk Lymphoma, 2015, 56(10), 2902-7.
- 17. Sullivan EM, Jeha S, Kang G, et al. NK cell genotype and phenotype at diagnosis of acute lymphoblastic leukemia correlate with postinduction residual disease. Clin Cancer Res, 2014, 20(23), 5986-94.
- 18. Misra MK, Prakash S, Moulik NR, et al. Genetic associations of killer immunoglobulin like receptors and class I human leukocyte antigens on childhood acute lymphoblastic leukemia among north Indians. Hum Immunol, 2016, 77(1), 41-6.
- 19. Sugioka DK, Gonçalves CE, Bicalho MD. KIR repertory in patients with hematopoietic diseases and healthy family members. BMC Hematology, 2016, 16, 25.
- 20. https://www.ebi.ac.uk/ipd/kir/
- 21. Varbanova V, Mihaylova A, Naumova E. Olerup SSP KIR HLA ligand typing Kit. A new opportunity for KIR ligand assignment in clinical settings. C R Acad Bulg Sci, 2010, 63(5), 713-722.
- 22. Gonzalez-Galarza F, Christmas S, Middleton D, Jones A. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Research, 2011, 39, D913-D919.
- 23. Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet, 1993, 52: 506-516.
- 24. Wall J, Pritchard J. Haplotypes blocks and linkage disequilibrium in the human genome. Nat Rev Genet, 2003, 4, 587-597.
- 25. Knapp M. The transmission/disequilibrium test and parental-genotype reconstruction: the reconstruction-combined transmission/disequilibrium test. Am J Hum Genet, 1999, 64, 861-870.
- 26. Spielman RS, Ewens WJ. A sibship test for linkage in the presence of association: the sib transmission/disequilibrium test. Am J Hum Genet, 1998, 62, 450-458.
- 27. Horvath S, Xu X, Laird NM. The family based association test method: strategies for studying general genotype–phenotype associations. Eur J Hum Genet, 2001, 9, 301-306.
- 28. Faure M, Longo E. KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential. J Immunol, 2002, 168, 6208-14.
- 29. Kikuchi-Maki A, Yusa S, Catina T, Cambpbell K. KIR2DL4 is an IL-2 regulated NK cells receptor that exhibits limited expression in humans but triggers strong IFN-gamma production. J Immunol, 2003, 171, 3415-3425.
- 30. Hsu K, Chida S, Geraghty D and Dupont B. The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunological Reviews, 2002, 190, 40-52.